# STARLITE-2: what one clinician is saying

> 2 statements from 3 sources (3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
- NCT ID: NCT05239533
- Registry: https://clinicaltrials.gov/study/NCT05239533
- Sponsor: Memorial Sloan Kettering Cancer Center
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: 177Lu-girentuximab plus nivolumab
- Indication: advanced clear cell renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 1de2e443d7f357376360843005f64715dda4b667e44d8f3009a7912ccc10ed4a

## Counts

- Commentary sources screened: 15
- Sources cited by verified statements: 3
- Verified statements: 2
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 2
- Findings: 2
- Named people in screened sources (unnamed speakers and accounts not counted): 1
- Speakers cited: 1
- Cited speakers with a verified identity: 1
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 1
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 1
- By role and specialty (the abstract's specialty counts):
  - 1 physician, Medical oncology

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist’s tentative interest in STARLITE-2 rests on a broader rationale for CAIX targeting, informed by RADICAL/A031801’s reported lack of symptomatic skeletal-event–free survival improvement with radium-223 added to cabozantinib. Their trial-specific discussion is limited to grouping it with STARLITE-1 and LUTEON, leaving this combination’s benefit, safety and treatment role unassessed.

## Question clinicians left open

What do clinicians need to see from STARLITE-2 to judge the role of CAIX-targeted 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma with bone metastases?

From findings F1 (1 statement from 1 speaker in 3 sources) and F2 (2 statements from 1 speaker in 3 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. RCC bone metastases: why a clinician considers CAIX-targeted therapy still in trials
  - 1 statement from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 1 cited clinicians.
- F2. RCC bone metastases: why a clinician questions whether bone-seeking therapy is enough
  - 2 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 1 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 1 | 3 | 3 | 1 | 2 |
| F2 | 2 | 3 | 3 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 3 posts and articles |
| F2 | 0 | 0 | 0 | 1 | 1 | 6 | 0 | 3 posts and articles |

### Trial dimensions

- Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximab: no finding draws on it directly
- Primary endpoint: Overall Response Rate/ORR: no finding draws on it directly
- Population and setting: F1 (1 shared claims), F2 (1 shared claims)
- The comparison: no finding draws on it directly
- Safety and tolerability: no finding draws on it directly
- Design and conduct: no finding draws on it directly

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MTD: maximum tolerated dose
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- RCC: renal cell carcinoma

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 2 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 2 | Paid |
| Who said each statement: the cited speakers | 1 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 7 | Free |
| Sources with links | 3 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 1 of the 1 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

2 discussed · 5 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximab | no commentary found | 0 | 0 |
| Primary endpoint: Overall Response Rate/ORR | no commentary found | 0 | 0 |
| Population and setting | discussed | 1 | 3 |
| The comparison (The registered arms and what clinicians said about how they compare.) | no commentary found | 0 | 0 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | no commentary found | 0 | 0 |
| CAIX targeting versus bone-seeking radioligands: indirect rationale from RADICAL/A031801 | discussed | 2 | 3 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 2 statements · 100%** | | | |
| X threads | 2 | 3 | 14 |
| LinkedIn posts | 0 | 0 | 1 |

- Screened window: 2022-05-10 to 2026-10-26
- Cited window: 2026-05-29 to 2026-05-29
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
- Registry: NCT05239533 (https://clinicaltrials.gov/study/NCT05239533)
- Study IDs: 21-328
- Sponsor: Memorial Sloan Kettering Cancer Center
- Design: Phase 2 · interventional, randomized, sequential, phase2
- Status: Active, not recruiting
- Enrollment: 9 (actual)
- Start: 2022-02-16 (actual)
- Primary completion: 2027-03 (estimated)
- Primary endpoint: Maximal tolerated dose (MTD) of 177Lu-girentuximab (24 (+/- 2) weeks)
- Primary endpoint: Overall Response Rate/ORR (24 (+/- 2) weeks)
- Intervention: 177Lu-labeled-girentuximab (drug)
- Intervention: Nivolumab (drug)
- Intervention: 89Zr-girentuximab PET/CT (diagnostic test)
- Intervention: 177Lu whole body (WB) planar and SPECT/CT scans (diagnostic test)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on presentation attribution for combined immunotherapy and targeted radioligand treatment in advanced clear-cell renal cell carcinoma.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- All substantive commentary supporting the findings comes from one author repeating the same text in three posts; it does not establish consensus or independent corroboration.
- The account groups several studies and treatment combinations together, leaving STARLITE-2-specific benefit, harms, patient selection and implementation unassessed.
- Comments that do not use the trial identifier or recorded study names, including wording and transcription variants, may be missing. The report is not a comprehensive account of public HCP discussion.
- An additional potentially relevant discussion is not represented because attribution of the presentations it relayed was incomplete; distinct views from that discussion may therefore be missing.
- No protocol was listed in the ClinicalTrials.gov material reviewed, and no publication for NCT05239533 or exact regulatory label for 177Lu-labeled-girentuximab was identified. These gaps limit independent clinical and regulatory contextualization of the account’s view.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-21 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 2 verified statements · 2 from 1 confirmed clinician
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/starlite-2-nct05239533/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=starlite-2-nct05239533

## Cite

Erudio Health. STARLITE-2 (NCT05239533): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/starlite-2-nct05239533

## Questions

### How much does the STARLITE-2 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the STARLITE-2 report cover?

2 statements from 3 sources (3 posts), 2 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the STARLITE-2 report?

Its preview, yes: get_report_card({ "slug": "starlite-2-nct05239533" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the STARLITE-2 report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/starlite-2-nct05239533.json
- Markdown: https://www.erudio.com/reports/starlite-2-nct05239533.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/starlite-2-nct05239533/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "starlite-2-nct05239533"}`
